Differential redox proteomic profiles of serum from severe asthma patients after one month of benralizumab and mepolizumab treatment

Differential redox proteomic profiles of serum from severe asthma patients after one month of benralizumab and mepolizumab treatment

Mepolizumab and Benralizumab are biological drugs for severe asthma patients able to reduce moderate-to-severe exacerbation rate (peripheral eosinophilial % mepolizumab 1.6 ± 1.2; benralizumab 0; p 

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pulmonary pharmacology & therapeutics 2021-10, Vol.70, p.102060-102060, Article 102060
Hauptverfasser: Landi, C., Vantaggiato, L., Shaba, E., Cameli, P., Carleo, A., d’Alessandro, M., Bergantini, L., Bargagli, E., Bini, L.
Format: Artikel
Sprache:eng
Schlagworte:
Benralizumab
Mepolizumab
Redox proteomics
Serum
Severe eosinophilic asthma
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Mepolizumab and Benralizumab are biological drugs for severe asthma patients able to reduce moderate-to-severe exacerbation rate (peripheral eosinophilial % mepolizumab 1.6 ± 1.2; benralizumab 0; p 
ISSN:1094-5539
1522-9629
DOI:10.1016/j.pupt.2021.102060